X4 Pharmaceuticals Files 8-K Report

Ticker: XFOR · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1501697

X4 Pharmaceuticals, Inc 8-K Filing Summary
FieldDetail
CompanyX4 Pharmaceuticals, Inc (XFOR)
Form Type8-K
Filed DateApr 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, filing

TL;DR

X4 Pharma updated its address and contact info in an 8-K filing.

AI Summary

On April 1, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts, 02134. The company's telephone number is (857) 529-8300. X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc. until September 20, 2010.

Why It Matters

This filing provides updated corporate information and addresses for X4 Pharmaceuticals, Inc., which is important for investors and stakeholders to have the most current contact and location details.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain information that suggests a significant change in the company's risk profile.

Key Numbers

  • 001-38295 — Commission File Number (Identifies the company's filing with the SEC)
  • 27-3181608 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • X4 Pharmaceuticals, Inc. (company) — Registrant
  • Arsanis, Inc. (company) — Former company name
  • April 1, 2024 (date) — Date of report
  • 61 North Beacon Street, 4th Floor, Boston, Massachusetts, 02134 (location) — Principal executive offices
  • 001-38295 (other) — Commission File Number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically updating the registrant's principal executive offices and contact information.

When was X4 Pharmaceuticals, Inc. formerly known as Arsanis, Inc.?

X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc. until September 20, 2010.

What is the address of X4 Pharmaceuticals, Inc.'s principal executive offices?

The address of X4 Pharmaceuticals, Inc.'s principal executive offices is 61 North Beacon Street, 4th Floor, Boston, Massachusetts, 02134.

What is the telephone number for X4 Pharmaceuticals, Inc.?

The telephone number for X4 Pharmaceuticals, Inc. is (857) 529-8300.

What is the Commission File Number for X4 Pharmaceuticals, Inc.?

The Commission File Number for X4 Pharmaceuticals, Inc. is 001-38295.

Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-04-01 09:20:03

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On April 1, 2024, X4 Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Investors" section of the Company's website at www.x4pharma.com. The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: April 1, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.